Curcumin: a natural substance with potential efficacy in Alzheimer’s disease

References

• PriceDLSisodiaSSGandySEAmyloid β amyloidosis in Alzheimer’s diseaseCurr Opin Neurol1995842682747582041
   PubMed Web of Science ®Google Scholar
• HebertLEWilsonRSGilleyDWDecline of language among women and men with Alzheimer’s diseaseJ Gerontol B Psychol Sci Soc Sci2000556P354P36011078105
   PubMed Web of Science ®Google Scholar
• www.alz.org [homepage on the Internet]Alzheimer’s Disease Facts and Figures Available from: http://www.alz.org/alzheimers_disease_facts_and_figures.aspAccessed April 8, 2013
   Google Scholar
• PalmerAMNeurochemical studies of Alzheimer’s diseaseNeurodegeneration1996543813919117551
   PubMedGoogle Scholar
• BartusRTDeanRL3rdBeerBLippaASThe cholinergic hypothesis of geriatric memory dysfunctionScience198221745584084147046051
   PubMed Web of Science ®Google Scholar
• HuntCETurnerAJCell biology, regulation and inhibition of β-secretase (BACE-1)FEBS J200927671845185919292866
   PubMed Web of Science ®Google Scholar
• LichtenthalerSFα-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potentialJ Neurochem20111161102121044078
   PubMed Web of Science ®Google Scholar
• ColeSLVassarRThe role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiologyJ Biol Chem200828344296212962518650431
   PubMed Web of Science ®Google Scholar
• BorcheltDRThinakaranGEckmanCBFamilial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1–42/1–40 ratio in vitro and in vivoNeuron1996175100510138938131
   PubMed Web of Science ®Google Scholar
• WolfeMSThe γ-secretase complex: membrane-embedded proteolytic ensembleBiochemistry200645267931793916800619
   PubMed Web of Science ®Google Scholar
• TwomeyCMcCarthyJVPresenilin-1 is an unprimed glycogen synthase kinase-3β substrateFEBS Lett2006580174015402016814287
   PubMed Web of Science ®Google Scholar
• DaRocha-SoutoBComaMPerez-NievasBGActivation of glycogen synthase kinase-3β mediates β-amyloid induced neuritic damage in Alzheimer’s diseaseNeurobiol Dis201245142543721945540
   PubMed Web of Science ®Google Scholar
• PeiJJTanakaTTungYCBraakEIqbalKGrundke-IqbalIDistribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brainJ Neuropathol Exp Neurol199756170788990130
   PubMed Web of Science ®Google Scholar
• TodaTNodaYItoGMaedaMShimizuTPresenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer’s diseaseJ Biomed Biotechnol2011201161797421234330
   PubMedGoogle Scholar
• SawamuraNMorishima-KawashimaMWakiHMutant presenilin 2 transgenic mice. A large increase in the levels of Aβ 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelinJ Biol Chem200027536279012790810846187
   PubMed Web of Science ®Google Scholar
• HsiaoKChapmanPNilsenSCorrelative memory deficits, Aβ elevation, and amyloid plaques in transgenic miceScience19962745284991028810256
   PubMed Web of Science ®Google Scholar
• WestermanMACooper-BlacketerDMariashAThe relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer’s diseaseJ Neurosci20022251858186711880515
   PubMed Web of Science ®Google Scholar
• GordonMNKingDLDiamondDMCorrelation between cognitive deficits and Aβ deposits in transgenic APP+PS1 miceNeurobiol Aging200122337738511378242
   PubMed Web of Science ®Google Scholar
• HardyJSelkoeDJThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience2002297558035335612130773
   PubMed Web of Science ®Google Scholar
• GoateAHardyJTwenty years of Alzheimer’s disease-causing mutationsJ Neurochem2012120Suppl 13822122678
   PubMed Web of Science ®Google Scholar
• CruchagaCHallerGChakravertySRare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease familiesPloS One201272e3103922312439
   PubMed Web of Science ®Google Scholar
• SisodiaSSPriceDLRole of the β-amyloid protein in Alzheimer’s diseaseFASEB J1995953663707896005
   PubMed Web of Science ®Google Scholar
• RoherAEEshCLKokjohnTAAmyloid β peptides in human plasma and tissues and their significance for Alzheimer’s diseaseAlzheimers Dement200951182919118806
   PubMed Web of Science ®Google Scholar
• DaviesLWolskaBHilbichCA4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniquesNeurology19883811168816933054625
   PubMed Web of Science ®Google Scholar
• KarSQuirionRAmyloid β peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer’s disease pathologyProg Brain Res200414526127414650921
   PubMed Web of Science ®Google Scholar
• KurtMADaviesDCKiddMPaired helical filament morphology varies with intracellular location in Alzheimer’s disease brainNeurosci Lett1997239141449547167
   PubMed Web of Science ®Google Scholar
• BallatoreCLeeVMTrojanowskiJQTau-mediated neurodegeneration in Alzheimer’s disease and related disordersNat Rev Neurosci20078966367217684513
   PubMed Web of Science ®Google Scholar
• GoedertMKlugACrowtherRATau protein, the paired helical filament and Alzheimer’s diseaseJ Alzheimers Dis20069Suppl 319520716914859
   PubMedGoogle Scholar
• AlberdiESanchez-GomezMVCavaliereFAmyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptorsCell Calcium201047326427220061018
   PubMed Web of Science ®Google Scholar
• KunerPSchubenelRHertelCβ-amyloid binds to p57NTR and activates NFκB in human neuroblastoma cellsJ Neurosci Res19985467988049856863
   PubMed Web of Science ®Google Scholar
• StrosznajderJBZambrzyckaAKacprzakMDStrosznajderRPAmyloid β peptide 25–35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortexJ Mol Neurosci199912210110910527454
   PubMed Web of Science ®Google Scholar
• LeeYJHanSBNamSYOhKWHongJTInflammation and Alzheimer’s diseaseArch Pharm Res201033101539155621052932
   PubMed Web of Science ®Google Scholar
• CaiZZhaoBRatkaAOxidative stress and β-amyloid protein in Alzheimer’s diseaseNeuromolecular Med201113422325021901428
   PubMed Web of Science ®Google Scholar
• AkiyamaHBargerSBarnumSInflammation and Alzheimer’s diseaseNeurobiol Aging200021338342110858586
   PubMed Web of Science ®Google Scholar
• McGeerEGMcGeerPLThe importance of inflammatory mechanisms in Alzheimer diseaseExp Gerontol19983353713789762518
   PubMed Web of Science ®Google Scholar
• NunomuraAPerryGAlievGOxidative damage is the earliest event in Alzheimer diseaseJ Neuropathol Exp Neurol200160875976711487050
   PubMed Web of Science ®Google Scholar
• ButterfieldDABoyd-KimballDAmyloid β-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brainBrain Pathol200414442643215605990
   PubMed Web of Science ®Google Scholar
• ChristenYOxidative stress and Alzheimer diseaseAm J Clin Nutr2000712621S629S10681270
   PubMed Web of Science ®Google Scholar
• YaoYChinniciCTangHTrojanowskiJQLeeVMPraticoDBrain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosisJ Neuroinflammation2004112115500684
   PubMed Web of Science ®Google Scholar
• SimpsonJEIncePGHaynesLJPopulation variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brainNeuropathol Appl Neurobiol2010361254019422529
   PubMed Web of Science ®Google Scholar
• AgostinhoPCunhaRAOliveiraCNeuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s diseaseCurr Pharm Des201016252766277820698820
   PubMed Web of Science ®Google Scholar
• BregmanNKarniAKorczynADCan treatment with nonsteroidal anti-inflammatory drugs protect from dementia?Arch Neurol200966453954019364945
   PubMedGoogle Scholar
• McNaullBBToddSMcGuinnessBPassmoreAPInflammation and anti-inflammatory strategies for Alzheimer’s disease – a mini-reviewGerontology201056131419752507
   PubMed Web of Science ®Google Scholar
• CahillCMLahiriDKHuangXRogersJTAmyloid precursor protein and α synuclein translation, implications for iron and inflammation in neurodegenerative diseasesBiochim Biophys Acta20091790761562819166904
   PubMed Web of Science ®Google Scholar
• ChoHHCahillCMVanderburgCRSelective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1J Biol Chem201028541312173123220558735
   PubMed Web of Science ®Google Scholar
• FisherACholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s diseaseNeurotherapeutics20085343344218625455
   PubMed Web of Science ®Google Scholar
• OsbornGGSaundersAVCurrent treatments for patients with Alzheimer diseaseJ Am Osteopath Assoc20101109 Suppl 8S16S2620926739
   PubMedGoogle Scholar
• AtriAShaughnessyLWLocascioJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer diseaseAlzheimer Dis Assoc Disord200822320922118580597
   PubMed Web of Science ®Google Scholar
• BirksJCholinesterase inhibitors for Alzheimer’s disease [review]Cochrane Database Syst Rev20061CD00559316437532
   PubMed Web of Science ®Google Scholar
• HansenRAGartlehnerGWebbAPMorganLCMooreCGJonasDEEfficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysisClin Interv Aging20083221122518686744
   PubMed Web of Science ®Google Scholar
• FisherACholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s diseaseJ Neurochem2012120Suppl 1223322122190
   PubMed Web of Science ®Google Scholar
• HerrmannNLiALanctotKMemantine in dementia: a review of the current evidenceExpert Opin Pharmacother201112578780021385152
   PubMed Web of Science ®Google Scholar
• McShaneRAreosa SastreAMinakaranNMemantine for dementia [review]Cochrane Database Syst Rev20062CD00315416625572
   PubMedGoogle Scholar
• MolinuevoJLGarcia-GilVVillarAMemantine: an antiglutamatergic option for dementiaAm J Alzheimers Dis Other Demen2004191101815002339
   PubMedGoogle Scholar
• BeachTGWalkerDGPotterPESueLIFisherAReduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonistsBrain Res20019051–222022311423097
   PubMed Web of Science ®Google Scholar
• FariasGGGodoyJAHernandezFAvilaJFisherAInestrosaNCM1 muscarinic receptor activation protects neurons from β-amyloid toxicity. A role for Wnt signaling pathwayNeurobiol Dis200417233734815474371
   PubMed Web of Science ®Google Scholar
• BordjiKBecerril-OrtegaJNicoleOBuissonAActivation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β productionJ Neurosci20103047159271594221106831
   PubMed Web of Science ®Google Scholar
• BordjiKBecerril-OrtegaJBuissonASynapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s diseaseRev Neurosci201122328529421568789
   PubMed Web of Science ®Google Scholar
• GoldeTEDisease modifying therapy for AD?J Neurochem200699368970717076654
   PubMed Web of Science ®Google Scholar
• Munoz-TorreroDAcetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s diseaseCurr Med Chem200815242433245518855672
   PubMed Web of Science ®Google Scholar
• BeusterienKMThomasSKGauseDKimelMArconaSMirskiDImpact of rivastigmine use on the risk of nursing home placement in a US sampleCNS Drugs200418151143114815581384
   PubMed Web of Science ®Google Scholar
• GeldmacherDSProvenzanoGMcRaeTMasteyVIeniJRDonepezil is associated with delayed nursing home placement in patients with Alzheimer’s diseaseJ Am Geriatr Soc200351793794412834513
   PubMed Web of Science ®Google Scholar
• McGeerPLSchulzerMMcGeerEGArthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studiesNeurology19964724254328757015
   PubMed Web of Science ®Google Scholar
• SastreMGentlemanSMNSAIDs: how they work and their prospects as therapeutics in Alzheimer’s diseaseFront Aging Neurosci201022020589102
   PubMed Web of Science ®Google Scholar
• Abdul-HaySOLuoJAshghodomRTThatcherGRNO-flurbiprofen reduces amyloid-β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockadeJ Neurochem2009111376677619702655
   PubMed Web of Science ®Google Scholar
• LeeRKWurtmanRJRegulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitorsAnn N Y Acad Sci200092026126811193162
   PubMed Web of Science ®Google Scholar
• TomitaTSecretase inhibitors and modulators for Alzheimer’s disease treatmentExpert Rev Neurother20099566167919402777
   PubMed Web of Science ®Google Scholar
• RogersJKirbyLCHempelmanSRClinical trial of indomethacin in Alzheimer’s diseaseNeurology1993438160916118351023
   PubMed Web of Science ®Google Scholar
• IntveldBARuitenbergAHofmanANonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s diseaseN Engl J Med2001345211515152111794217
   PubMed Web of Science ®Google Scholar
• MartinBKSzekelyCBrandtJADAPT Research GroupCognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxibArch Neurol200865789690518474729
   PubMedGoogle Scholar
• MeinertCLMcCaffreyLDBreitnerJCADAPT Research Group. Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline resultsAlzheimers Dement2009529310419328435
   PubMed Web of Science ®Google Scholar
• HaydenKMZandiPPKhachaturianASDoes NSAID use modify cognitive trajectories in the elderly? The Cache County studyNeurology200769327528217636065
   PubMed Web of Science ®Google Scholar
• EtminanMGillSSamiiAEffect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studiesBMJ2003327740712812869452
   PubMed Web of Science ®Google Scholar
• ChandraVPandavRDodgeHHIncidence of Alzheimer’s disease in a rural community in India: the Indo–US studyNeurology200157698598911571321
   PubMed Web of Science ®Google Scholar
• ShajiSBoseSVergheseAPrevalence of dementia in an urban population in Kerala, IndiaBr J Psychiatry200518613614015684237
   PubMed Web of Science ®Google Scholar
• VasCJPintoCPanikkerDPrevalence of dementia in an urban Indian populationInt Psychogeriatr200113443945012003250
   PubMed Web of Science ®Google Scholar
• WardACreanSMercaldiCJPrevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysisNeuroepidemiology201238111722179327
   PubMed Web of Science ®Google Scholar
• GanguliMChandraVKambohMIApolipoprotein E polymorphism and Alzheimer disease: the Indo–US cross-national dementia studyArch Neurol200057682483010867779
   PubMedGoogle Scholar
• AltamuraCSquittiRPasqualettiPWhat is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?Eur J Neurol200714667968217539949
   PubMed Web of Science ®Google Scholar
• AndreasenNHesseCDavidssonPCerebrospinal fluid β-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of diseaseArch Neurol199956667368010369305
   PubMedGoogle Scholar
• Ahn JoSAhnKKimJHApoE-ε 4-dependent association of the choline acetyltransferase gene polymorphisms (2384G > A and 1882G > A) with Alzheimer’s diseaseClin Chim Acta20063681–217918216480703
   PubMed Web of Science ®Google Scholar
• KandimallaRJSPBkBCerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer’s disease patientsNeurosci Lett2011487213413820599474
   PubMed Web of Science ®Google Scholar
• SubramanianSSandhyaraniBShreeANDLower levels of cerebrospinal fluid amyloid β (Aβ) in non-demented Indian controlsNeurosci Lett2006407212112316978775
   PubMed Web of Science ®Google Scholar
• CommandeurJNVermeulenNPCytotoxicity and cytoprotective activities of natural compounds. The case of curcuminXenobiotica19962676676808819298
   PubMed Web of Science ®Google Scholar
• JoeBLokeshBRRole of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophagesBiochim Biophys Acta1994122422552637981240
   PubMed Web of Science ®Google Scholar
• ReddyACLokeshBRStudies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomesMol Cell Biochem19921111–21171241588934
   PubMed Web of Science ®Google Scholar
• MenonVPSudheerARAntioxidant and anti-inflammatory properties of curcuminAdv Exp Med Biol200759510512517569207
   PubMed Web of Science ®Google Scholar
• RaoTSBasuNSiddiquiHHAnti-inflammatory activity of curcumin analoguesIndian J Med Res1982755745787118227
   PubMed Web of Science ®Google Scholar
• AggarwalBBSungBPharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targetsTrends Pharmacol Sci2009302859419110321
   PubMed Web of Science ®Google Scholar
• FrautschySAColeGMWhy pleiotropic interventions are needed for Alzheimer’s diseaseMol Neurobiol2010412–339240920437209
   PubMed Web of Science ®Google Scholar
• RingmanJMFrautschySAColeGMMastermanDLCummingsJLA potential role of the curry spice curcumin in Alzheimer’s diseaseCurr Alzheimer Res20052213113615974909
   PubMedGoogle Scholar
• WahlstromBBlennowGA study on the fate of curcumin in the ratActa Pharmacol Toxicol (Copenh)19784328692696348
   PubMedGoogle Scholar
• LaoCDRuffinMT4thNormolleDDose escalation of a curcuminoid formulationBMC Complement Altern Med200661016545122
   PubMedGoogle Scholar
• GoelAKunnumakkaraABAggarwalBBCurcumin as “curecumin”: from kitchen to clinicBiochem Pharmacol200875478780917900536
   PubMed Web of Science ®Google Scholar
• AnandPKunnumakkaraABNewmanRAAggarwalBBBioavailability of curcumin: problems and promisesMol Pharm20074680781817999464
   PubMed Web of Science ®Google Scholar
• SharmaRAMcLellandHRHillKAPharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancerClin Cancer Res2001771894190011448902
   PubMed Web of Science ®Google Scholar
• DarveshASCarrollRTBishayeeANovotnyNAGeldenhuysWJVan der SchyfCJCurcumin and neurodegenerative diseases: a perspectiveExpert Opin Invest Drugs201221811231140
   PubMed Web of Science ®Google Scholar
• GuptaSCPatchvaSKohWAggarwalBBDiscovery of curcumin, a component of golden spice, and its miraculous biological activitiesClin Exp Pharm Physiol2012393283299
   PubMed Web of Science ®Google Scholar
• SchraufstatterEBerntHAntibacterial action of curcumin and related compoundsNature1949164416745618140450
   PubMed Web of Science ®Google Scholar
• DovigoLNPavarinaACCarmelloJCMachadoALBrunettiILBagnatoVSSusceptibility of clinical isolates of Candida to photodynamic effects of curcuminLasers Surg Med201143992793422006736
   PubMed Web of Science ®Google Scholar
• NeelofarKShreazSRimpleBMuralidharSNikhatMKhanLACurcumin as a promising anticandidal of clinical interestCan J Microbiol201157320421021358761
   PubMed Web of Science ®Google Scholar
• ZandiKRamedaniEMohammadiKEvaluation of antiviral activities of curcumin derivatives against HSV-1 in Vero cell lineNat Prod Commun20105121935193821299124
   PubMed Web of Science ®Google Scholar
• KolodziejczykJOlasBSaluk-JuszczakJWachowiczBAntioxidative properties of curcumin in the protection of blood platelets against oxidative stress in vitroPlatelets201122427027621303217
   PubMed Web of Science ®Google Scholar
• SandurSKIchikawaHPandeyMKRole of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane)Free Radic Biol Med200743456858017640567
   PubMed Web of Science ®Google Scholar
• SandurSKPandeyMKSungBCurcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanismCarcinogenesis20072881765177317522064
   PubMed Web of Science ®Google Scholar
• ShenLJiHFThe pharmacology of curcumin: is it the degradation products?Trends Mol Med201218313814422386732
   PubMed Web of Science ®Google Scholar
• KimDSParkSYKimJKCurcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1–42) insultNeurosci Lett20013031576111297823
   PubMed Web of Science ®Google Scholar
• ChhunchhaBFatmaNKuboERaiPSinghSPSinghDPCurcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-κB regulationAm J Physiol Cell Physiol1302013 Epub ahead of print
   Web of Science ®Google Scholar
• GiriRKRajagopalVKalraVKCurcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factorJ Neurochem20049151199121015569263
   PubMed Web of Science ®Google Scholar
• QinXYChengYYuLCPotential protection of curcumin against intracellular amyloid β-induced toxicity in cultured rat prefrontal cortical neuronsNeurosci Lett20104801212420638958
   PubMed Web of Science ®Google Scholar
• HuangHCChangPDaiXLJiangZFProtective effects of curcumin on amyloid-β-induced neuronal oxidative damageNeurochem Res20123771584159722476982
   PubMed Web of Science ®Google Scholar
• ZhangXYinWKShiXDLiYCurcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cellsEur J Pharm Sci201142554054621352912
   PubMed Web of Science ®Google Scholar
• OnoKHasegawaKNaikiHYamadaMCurcumin has potent anti-amyloidogenic effects for Alzheimer’s β-amyloid fibrils in vitroJ Neurosci Res200475674275014994335
   PubMed Web of Science ®Google Scholar
• YangFLimGPBegumANCurcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivoJ Biol Chem200528075892590115590663
   PubMed Web of Science ®Google Scholar
• ZhaoLNChiuSWBenoitJChewLYMuYThe effect of curcumin on the stability of Aβ dimersJ Phys Chem B2012116257428743522690789
   PubMed Web of Science ®Google Scholar
• OrlandoRAGonzalesAMRoyerREDeckLMVander JagtDLA chemical analog of curcumin as an improved inhibitor of amyloid Aβ oligomerizationPloS One201273e3186922442659
   PubMed Web of Science ®Google Scholar
• LiuHLiZQiuDGuQLeiQMaoLThe inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cellsNeurosci Lett20104852838820727383
   PubMed Web of Science ®Google Scholar
• ZhangCBrowneAChildDTanziRECurcumin decreases amyloid-β peptide levels by attenuating the maturation of amyloid-β precursor proteinJ Biol Chem201028537284722848020622013
   PubMed Web of Science ®Google Scholar
• ZhangXZhangHMSiLLiYCurcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s diseasePharmacol Rep20116351101110822180352
   PubMed Web of Science ®Google Scholar
• JiaoYWilkinsonJ4thDiXCurcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelatorBlood2009113246246918815282
   PubMed Web of Science ®Google Scholar
• DaiMCZhongZHSunYHCurcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosisNeurosci Lett2013536414623328441
   PubMed Web of Science ®Google Scholar
• BaumLNgACurcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal modelsJ Alzheimers Dis20046436737715345806
   PubMed Web of Science ®Google Scholar
• LimGPChuTYangFBeechWFrautschySAColeGMThe curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouseJ Neurosci200121218370837711606625
   PubMed Web of Science ®Google Scholar
• LimGPYangFChuTIbuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic miceNeurobiol Aging200122698399111755007
   PubMed Web of Science ®Google Scholar
• BegumANJonesMRLimGPCurcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s diseaseJ Pharmacol Exp Ther2008326119620818417733
   PubMed Web of Science ®Google Scholar
• AhmedTEnamSAGilaniAHCurcuminoids enhance memory in an amyloid-infused rat model of Alzheimer’s diseaseNeuroscience201016931296130620538041
   PubMed Web of Science ®Google Scholar
• AhmedTGilaniAHA comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Aβ plus ibotenic acid-infused rat model of Alzheimer’s diseaseBrain Res2011140011821640982
   PubMed Web of Science ®Google Scholar
• MaQLYangFRosarioERβ-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcuminJ Neurosci200929289078908919605645
   PubMed Web of Science ®Google Scholar
• BaumLLamCWCheungSKSix-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer diseaseJ Clin Psychopharmacol200828111011318204357
   PubMed Web of Science ®Google Scholar
• RingmanJMFrautschySATengEOral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled studyAlzheimers Res Ther2012454323107780
   PubMed Web of Science ®Google Scholar
• RingmanJMColeGMTengEOral curcumin for the treatment of mild-to-moderate Alzheimer’s disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week studyAlzheimers Dement20084Suppl 4T774
   Google Scholar
• www.clinicaltrials.gov [homepage on the Internet] http://www.alz.org/alzheimers_disease_facts_and_figures.aspAccessed April 8, 2013
   Google Scholar
• www.alzforum.org [homepage on the Internet]Drugs in Clinical Trials Available from: http://www.alzforum.org/drg/drc/detail.asp?id=137Accessed April 8, 2013
   Google Scholar
• MancusoCSicilianoRBaroneECurcumin and Alzheimer disease: this marriage is not to be performedJ Biol Chem20112863le321239508
   PubMed Web of Science ®Google Scholar
• ChengALHsuCHLinJKPhase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesionsAnticancer Res2001214B2895290011712783
   PubMed Web of Science ®Google Scholar
• ShobaGJoyDJosephTMajeedMRajendranRSrinivasPSInfluence of piperine on the pharmacokinetics of curcumin in animals and human volunteersPlanta Med19986443533569619120
   PubMed Web of Science ®Google Scholar
• BelkacemiADogguiSDaoLRamassamyCChallenges associated with curcumin therapy in Alzheimer diseaseExpert Rev Mol Med201113e3422051121
   PubMed Web of Science ®Google Scholar
• ChenSYChenYLiYPDesign, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer’s diseaseBioorg Med Chem201119185596560421840724
   PubMed Web of Science ®Google Scholar
• BolognesiMLBartoliniMTarozziAMultitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entityBioorg Med Chem Lett20112192655265821236667
   PubMed Web of Science ®Google Scholar
• DadhaniyaPPatelCMuchharaJSafety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studiesFood Chem Toxicol20114981834184221571027
   PubMed Web of Science ®Google Scholar
• ManjuSSreenivasanKConjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stabilityJ Colloid Interface Sci2011359131832521492865
   PubMed Web of Science ®Google Scholar
• ManjuSSreenivasanKHollow microcapsules built by layer by layer assembly for the encapsulation and sustained release of curcuminColloids Surf B Biointerfaces201182258859321051207
   PubMed Web of Science ®Google Scholar
• ManjuSSreenivasanKSynthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugateJ Pharm Sci2011100250451120848656
   PubMed Web of Science ®Google Scholar
• GuptaNKDixitVKBioavailability enhancement of curcumin by complexation with phosphatidyl cholineJ Pharm Sci201110051987199521374628
   PubMed Web of Science ®Google Scholar
• SetthacheewakulSMahattanadulSPhadoongsombutNPichayakornWWiwattanapatapeeRDevelopment and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in ratsEur J Pharm Biopharm201076347548520659556
   PubMed Web of Science ®Google Scholar
• TakahashiMUechiSTakaraKAsikinYWadaKEvaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcuminJ Agric Food Chem200957199141914619757811
   PubMed Web of Science ®Google Scholar
• ManjuSSreenivasanKGold nanoparticles generated and stabilized by water soluble curcumin–polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cellsJ Colloid Interface Sci2012368114415122200330
   PubMed Web of Science ®Google Scholar
• GhoshDChoudhurySTGhoshSNanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in ratChem Biol Interact2012195320621422197969
   PubMed Web of Science ®Google Scholar
• GhoshMSinghATXuWSulchekTGordonLIRyanROCurcumin nanodisks: formulation and characterizationNanomedicine20117216216720817125
   PubMed Web of Science ®Google Scholar
• ShaikhJAnkolaDDBeniwalVSinghDKumarMNNanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancerEur J Pharm Sci2009373–422323019491009
   PubMed Web of Science ®Google Scholar
• YallapuMMGuptaBKJaggiMChauhanSCFabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cellsJ Colloid Interface Sci20103511192920627257
   PubMed Web of Science ®Google Scholar
• MohantyCSahooSKThe in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulationBiomaterials201031256597661120553984
   PubMed Web of Science ®Google Scholar
• DebnathSSaloumDDolaiSDendrimer–curcumin conjugate: a water soluble and effective cytotoxic agent against breast cancer cell linesAnticancer Agents Med Chem1242013 Epub ahead of print
   Web of Science ®Google Scholar
• ChengKKYeungCFHoSWChowSFChowAHBaumLHighly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer’s disease Tg2576 miceAAPS J12112012 Epub ahead of print
   Web of Science ®Google Scholar
• DuboisBFeldmanHHJacovaCRevising the definition of Alzheimer’s disease: a new lexiconLancet Neurol20109111118112720934914
   PubMed Web of Science ®Google Scholar
• GoldeTESchneiderLSKooEHAnti-Aβ therapeutics in Alzheimer’s disease: the need for a paradigm shiftNeuron201169220321321262461
   PubMed Web of Science ®Google Scholar
• JanusCPearsonJMcLaurinJAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s diseaseNature2000408681597998211140685
   PubMed Web of Science ®Google Scholar
• MorganDDiamondDMGottschallPEAβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s diseaseNature2000408681598298511140686
   PubMed Web of Science ®Google Scholar
• NicollJAWilkinsonDHolmesCSteartPMarkhamHWellerRONeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNat Med20039444845212640446
   PubMed Web of Science ®Google Scholar
• BlennowKZetterbergHWeiJLiuEBlackRGrundmanMImmunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer’s diseaseAlzheimers Dement20106Suppl 4S134S135
   Google Scholar
• LaskowitzDTKollsBJA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology20107424202620548049
   PubMed Web of Science ®Google Scholar
• DeMattosRBRackeMMGelfanovaVIdentification, characterization, and comparison of amino-terminally truncated Aβ42 peptides in Alzheimer’s disease brain tissue and in plasma from Alzheimer’s patients receiving solanezumab immunotherapy treatmentAlzheimers Dement20095Suppl 4P156P157
   Google Scholar
• BatemanRJSiemersERMawuenyegaKGA γ-secretase inhibitor decreases amyloid-β production in the central nervous systemAnn Neurol2009661485419360898
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyLilly halts development of semagacestat for Alzheimer’s disease based on preliminary results of Phase III clinical trials [press release]Indianapolis, INEli Lilly and Company2012817 Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=499794Accessed March 8, 2013
   Google Scholar
• ParachikovaAGreenKNHendrixCLaFerlaFMFormulation of a medical food cocktail for Alzheimer’s disease: beneficial effects on cognition and neuropathology in a mouse model of the diseasePloS One2010511e1401521103342
   PubMed Web of Science ®Google Scholar
• DavinelliSSapereNZellaDBracaleRIntrieriMScapagniniGPleiotropic protective effects of phytochemicals in Alzheimer’s diseaseOxid Med Cell Longev2012201238652722690271
   PubMed Web of Science ®Google Scholar